Abstract
The fervor surrounding immunotherapy has resulted in an unprecedented progression from safety and efficacy studies to large-scale randomized trials across the oncology trials landscape. As we embark on the journey of investigating these new agents, we should pause to remember the successes and mistakes of the past. Championing the role of the quality assurance in radiotherapy (RT-QA) clinical trials is one of these successes.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Radiation Oncology, Biology, Physics
Paper Title
Journal
Date
